Efficacy of a canarypox virus-vectored vaccine against feline leukaemia
- H. Poulet, DVM1,
- S. Brunet, PhD1,
- C. Boularand, DVM1,
- A. L. Guiot, DVM, PhD1,
- V. Leroy, BSc1,
- J. Tartaglia, PhD2,
- J. Minke, DVM, PhD1,
- J. C. Audonnet, DVM, PhD1 and
- P. Desmettre, DVM1
Canarypox virus recombinant vaccines have a unique efficacy and safety profile for the vaccinated host because the canarypox virus is non-replicative in mammalian hosts. After the vaccination of a mammalian species, recombinant canarypox viruses express the inserted genes but cannot multiply in the host. They stimulate a strong immune response in the absence of any virus amplification in the host or any viral spread into the environment. A new canarypox-based recombinant vaccine is the canarypox-feline leukaemia virus (FeLV) vaccine (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes. This paper describes experiments which demonstrate that it is effective against any oronasal FeLv challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe ‘in-contact’ challenge. Furthermore, the canarypox virus-FeLv vaccine was effective without an adjuvant.
- British Veterinary Association. All rights reserved.